Subsequently, this team conducted a serious of phase I and II studies to determine the efficacy of DC vaccines targeting HER-2 in patients with DCIS and different subtypes of BC (Sharma et al., 2012; Datta et al., 2015). Here, ERBB2 is linked to ductal breast carcinoma in situ.